PharmaEssentia Reports 49% Year-Over-Year Growth in May Revenue, Driven by Steady Sales of Blood Cancer Drug

PharmaEssentia announced yesterday (June 5) that its consolidated revenue for May reached NT$1.18 billion, representing a 49.15% year-over-year increase. The strong performance was primarily fueled by stable sales of its rare blood cancer therapy, Ropeginterferon alfa-2b (Ropeg or P1101), in the U.S. market.